Evidence map›Paper›PMID 36092733›Full record

ReviewFrontiers in cell and developmental biology2022

It takes two to tango: Widening our understanding of the onset of schizophrenia from a neuro-angiogenic perspective.

Bárbara S Casas, David Arancibia-Altamirano, Franco Acevedo-La Rosa, Delia Garrido-Jara, Vera Maksaev, Dan Pérez-Monje, Verónica Palma

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bárbara S CasasLaboratory of Stem Cells and Developmental Biology, Departamento de Biología, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.
David Arancibia-AltamiranoLaboratory of Stem Cells and Developmental Biology, Departamento de Biología, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.
Franco Acevedo-La RosaLaboratory of Stem Cells and Developmental Biology, Departamento de Biología, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.
Delia Garrido-JaraLaboratory of Stem Cells and Developmental Biology, Departamento de Biología, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.
Vera MaksaevLaboratory of Stem Cells and Developmental Biology, Departamento de Biología, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.
Dan Pérez-MonjeLaboratory of Stem Cells and Developmental Biology, Departamento de Biología, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.
Verónica PalmaLaboratory of Stem Cells and Developmental Biology, Departamento de Biología, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.
University of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia is a chronic debilitating mental disorder characterized by perturbations in thinking, perception, and behavior, along with brain connectivity deficiencies, neurotransmitter dysfunctions, and loss of gray brain matter. To date, schizophrenia has no cure and pharmacological treatments are only partially efficacious, with about 30% of patients describing little to no improvement after treatment. As in most neurological disorders, the main descriptions of schizophrenia physiopathology have been focused on neural network deficiencies. However, to sustain proper neural activity in the brain, another, no less important network is operating: the vast, complex and fascinating vascular network. Increasing research has characterized schizophrenia as a systemic disease where vascular involvement is important. Several neuro-angiogenic pathway disturbances have been related to schizophrenia. Alterations, ranging from genetic polymorphisms, mRNA, and protein alterations to microRNA and abnormal metabolite processing, have been evaluated in plasma, post-mortem brain, animal models, and patient-derived induced pluripotent stem cell (hiPSC) models. During embryonic brain development, the coordinated formation of blood vessels parallels neuro/gliogenesis and results in the structuration of the neurovascular niche, which brings together physical and molecular signals from both systems conforming to the Blood-Brain barrier. In this review, we offer an upfront perspective on distinctive angiogenic and neurogenic signaling pathways that might be involved in the biological causality of schizophrenia. We analyze the role of pivotal angiogenic-related pathways such as Vascular Endothelial Growth Factor and HIF signaling related to hypoxia and oxidative stress events; classic developmental pathways such as the NOTCH pathway, metabolic pathways such as the mTOR/AKT cascade; emerging neuroinflammation, and neurodegenerative processes such as UPR, and also discuss non-canonic angiogenic/axonal guidance factor signaling. Considering that all of the mentioned above pathways converge at the Blood-Brain barrier, reported neurovascular alterations could have deleterious repercussions on overall brain functioning in schizophrenia.

Indexed as

angiogenesisblood-brain barrierbrain developmenthiPSCneurogenesisneurovascular nicheschizophrenia

Identifiers

PMID36092733
PMCPMC9448889
OpenAlexW4292877750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.